REMD-477 (Volagidemab)
Type 1 Diabetes
Key Facts
About REMD Biotherapeutics
REMD Biotherapeutics is a clinical-stage biotech leveraging expertise in GPCR-targeting antibodies and bispecific platforms to develop novel treatments. Its lead asset, Volagidemab, is an anti-glucagon receptor antibody with promising Phase 2 data in Type 1 and Type 2 diabetes and is being explored in obesity and oncology-related hyperglycemia. The company operates with a dual-US/China footprint and has established key strategic partnerships, notably with GenScript ProBio and Buchang Pharmaceutical, to advance its pipeline and platform technologies.
View full company profileAbout REMD Biotherapeutics
REMD Biotherapeutics is a clinical-stage biotech leveraging expertise in GPCR-targeting antibodies and bispecific platforms to develop novel treatments. Its lead asset, Volagidemab, is an anti-glucagon receptor antibody with promising Phase 2 data in Type 1 and Type 2 diabetes and is being explored in obesity and oncology-related hyperglycemia. The company operates with a dual-US/China footprint and has established key strategic partnerships, notably with GenScript ProBio and Buchang Pharmaceutical, to advance its pipeline and platform technologies.
View full company profileAbout REMD Biotherapeutics
REMD Biotherapeutics is a clinical-stage biotech leveraging expertise in GPCR-targeting antibodies and bispecific platforms to develop novel treatments. Its lead asset, Volagidemab, is an anti-glucagon receptor antibody with promising Phase 2 data in Type 1 and Type 2 diabetes and is being explored in obesity and oncology-related hyperglycemia. The company operates with a dual-US/China footprint and has established key strategic partnerships, notably with GenScript ProBio and Buchang Pharmaceutical, to advance its pipeline and platform technologies.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |